Phase IIb programme of IPP 204106 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer or pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2013
At a glance
- Drugs IPP 204106 (Primary)
- Indications Glioblastoma; Malignant melanoma; Pancreatic cancer; Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 13 Aug 2013 This trial is progressing according to protocol, according to an ImmuPharma media release.
- 06 Dec 2010 New trial record
- 19 Nov 2010 ImmuPharma plans to file a US IND for IPP 204106 in the next few months, according to a company media release.